Ticker Details
Axon Holdings S.A. Axovant Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of dementia.
IPO Date:	June 11, 2015
Sector:	Industrials
Industry:	Aerospace and Defense
Market Cap:	$51B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$4.33 | 2.72%
Avg Daily Range (30 D):	$19.76 | 3.48%
Avg Daily Range (90 D):	$16.18 | 3.29%

Institutional Daily Volume
Avg Daily Volume:	.63M
Avg Daily Volume (30 D):	.72M
Avg Daily Volume (90 D):	.91M

Trade Size
Avg Trade Size (Sh.):	58
Avg Trade Size (Sh.) (30 D):	19
Avg Trade Size (Sh.) (90 D):	20

Institutional Trades
Total Institutional Trades:	3,811
Avg Institutional Trade:	$17.85M
Avg Institutional Trade (30 D):	$40.48M
Avg Institutional Trade (90 D):	$35.23M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$32.05M
Avg Closing Trade (30 D):	$64.4M
Avg Closing Trade (90 D):	$68.64M
Avg Closing Volume:	91.22K

News

Aug 8, 2026 @ 9:23 AM $10,000 in Axon Stock a Decade Ago Would Be Worth ... Source: Daniel Sparks

Aug 6, 2026 @ 3:15 PM Axon Enterprise vs. Booking: Which Stock Is a Bett... Source: Sara Appino

Aug 5, 2026 @ 6:32 PM Airbnb vs. Axon Enterprise: Which Consumer Stock I... Source: Brendan Coffey

Aug 4, 2026 @ 7:09 PM Axon Enterprise vs. Beyond Meat: Which Stock Is a ... Source: Brendan Coffey

Jul 15, 2026 @ 3:08 PM 5 Stocks to Buy If the Market Drops Again Source: Neil Rozenbaum

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$.37	$2.11	$.03
Diluted EPS	$.36	$2.05	$.03
Revenue	$904.39M	$807.35M	$796.72M
Gross Profit	$546.45M	$477.29M	$461.3M
Net Income / Loss	$29.43M	$169.31M	$2.75M
Operating Income / Loss	$46.78M	$29.24M	$-50.12M
Cost of Revenue	$357.94M	$330.06M	$335.43M
Net Cash Flow	$138.47M	$-742.24M	$-222.75M
PE Ratio

Splits
Sep 28, 2007	1:600
Nov 30, 2004	2:1
Apr 30, 2004	2:1
Feb 11, 2004	3:1